Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Acute kidney injury (AKI) complicates 5% to 40% of major cardiovascular surgeries requiring cardiopulmonary bypass. Dexmedetomidine has been proposed as a potential renoprotective agent in the perioperative period, but its impact on postoperative renal outcomes remains uncertain. This study aimed to evaluate whether intraoperative dexmedetomidine administration reduces the incidence of postoperative AKI after on-pump cardiovascular surgery and to assess effect heterogeneity across clinical subgroups.
We conducted a retrospective cohort study using longitudinal electronic health records from four tertiary cardiac centers in China. Adult patients who underwent on-pump cardiovascular surgeries between December 2016 and August 2024 were included. After excluding 13,262 patients based on predefined criteria, the final cohort consisted of 20,553 patients (8,688 received intraoperative dexmedetomidine and 11,865 did not). Dexmedetomidine exposure was defined as continuous infusion initiated before incision and maintained intraoperatively for at least 120 minutes at a rate of ≥0.1 μg/kg/h. Two hypothetical cohorts were constructed for target trial emulation: a dynamic intervention group receiving intraoperative dexmedetomidine and a static control group not receiving intraoperative administration. The primary outcome was the incidence of Kidney Disease: Improving Global Outcomes (KDIGO)-defined AKI within 7 days postoperatively, assuming complete follow-up through day 7 after surgery.
Dexmedetomidine recipients were slightly younger (mean age, 51.4 vs 52.2 years) and had a lower body mass index (23.1 vs 23.5 kg/m²). Under the modified treatment policy, the estimated incidence of stage ≥1 postoperative AKI was 28.4% in the dexmedetomidine group vs 29.1% in the non-dexmedetomidine group (risk difference, –0.8%; 95% CI, –1.4% to –0.1%; relative risk [RR], 0.99; 95% CI, 0.98 to 1.00). For stage ≥2 AKI and stage 3 AKI, the estimated incidences were 9.0% vs 9.3% (RR, 1.00; 95% CI, 0.99 to 1.00) and 4.7% vs 4.4% (RR, 1.00; 95% CI, 1.00 to 1.01). Sensitivity analyses confirmed the robustness of these findings and suggested a possible protective effect against stage 3 AKI with extended postoperative dexmedetomidine administration.
Our multicenter cohort study found no significant association between intraoperative dexmedetomidine use and a reduced risk of postoperative AKI. These findings provide preliminary evidence to inform clinical practice, although prospective validation is needed to assess long-term renal effects.
